secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K/A
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001628280-24-036343
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions corrects Q2 earnings; raises full-year revenue guidance to $99-101M
--------------------------------------------------------------------------------

- Q2 total revenue $28.3M, down 3% YoY but up 6% sequentially; Cell Processing up 11% sequentially.
- GAAP net loss from continuing ops $7.1M (incl $4.1M write-off) versus $5.5M loss a year ago.
- Non-GAAP adjusted EBITDA $4.8M or 17% of revenue, up from $1.7M or 6% in Q2 2023.
- FY 2024 total revenue guidance raised to $99-101M; Cell Processing guidance raised to $70-71M.
- 8-K/A corrects prior release to reduce stock compensation by $2.1M from discontinued operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828024036343/0001628280-24-036343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828024036343/blfs-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-036343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer